Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 studyArthur Bobin, Xavier Leleu, Salomon Manier et al.|Haematologica|2024Cited by 3
Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLGPeter Mollee, Murielle Roussel, Laure Vincent et al.|Blood|2024Cited by 3
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY StudyTitouan Cazaubiel, Cyrille Hulin, Bruno Royer et al.|Clinical Hematology International|2025Cited by 2
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette et al.|Research Square|2025Cited by 0